Zacks Investment Research cut shares of Arch Therapeutics Inc (NASDAQ:ARTH) from a buy rating to a hold rating in a research note released on Wednesday, October 18th.
According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “
Other equities research analysts have also recently issued reports about the stock. HC Wainwright set a $3.00 price target on shares of Arch Therapeutics and gave the stock a buy rating in a research report on Thursday, July 27th. ValuEngine upgraded shares of Arch Therapeutics from a sell rating to a hold rating in a research report on Saturday, August 26th. Finally, Ifs Securities reiterated an outperform rating on shares of Arch Therapeutics in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Arch Therapeutics presently has an average rating of Buy and a consensus target price of $2.31.
Arch Therapeutics (NASDAQ:ARTH) traded up 0.0509% on Wednesday, hitting $0.7854. 97,207 shares of the company’s stock were exchanged. Arch Therapeutics has a 12-month low of $0.41 and a 12-month high of $0.89. The company’s 50-day moving average price is $0.80 and its 200-day moving average price is $0.64. The company’s market cap is $115.47 million.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/arch-therapeutics-inc-arth-downgraded-by-zacks-investment-research.html.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.